ニュース · QuantAbundancia

Exec Edge13d agoneutral

Glucotrack Submits Blood Glucose Monitoring Technology to FDA

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed to deliver real-time glucose readings without the need for an external wearable device. “Submission of […]

Simply Wall St.13d agoneutral

Abbott Cardiac Data Sheds Light On Heart Rhythm Pipeline And Earnings Story

Abbott Laboratories (NYSE:ABT) released new late breaking clinical data on its advanced cardiac devices, focusing on pulsed field ablation and conduction system pacing. The data highlights patient outcomes for the TactiFlex Duo Ablation Catheter, UltiSynq CSP ICD lead, and AVEIR CSP leadless pacemaker in complex heart rhythm disorders. These results add fresh detail on Abbott's electrophysiology and device pipeline beyond its recently covered AI enabled imaging approvals. For anyone...

Motley Fool14d agoneutral

Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

ABT MCD PG

Barchart15d agoneutral

Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payer

Abbott’s business and dividend story remain intact even as the stock trades near 52‑week lows.

ABT

Zacks15d agoneutral

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

ABT

Exec Edge16d agoneutral

Agilent Technologies Names Michael Buckner as CLO

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it designated Michael Buckner as Chief Legal Officer, having previously served at Danaher as Vice President, Deputy General Counsel, and Chief M&A Counsel. Mr. Buckner has nearly 30 years of experience as a senior global legal executive with experience in complex transactions and regulatory environments, the […]

ABT

Motley Fool18d agobullish

1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever

This company, which has raised its dividend for 54 consecutive years, is on sale.

ABT

Insider Monkey19d agoneutral

Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software

Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. Management stated that the milestone marks a considerable step forward for the […]

ABT

Reuters20d agoneutral

Dexcom reaffirms full-year forecast after topping quarterly estimates

April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its

ABT

Simply Wall St.20d agoneutral

How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0

Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that integrates high‑resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions. This positions Abbott at the forefront of AI-guided cardiovascular care, potentially making OCT a more intuitive, workflow-friendly tool for treating challenging coronary disease cases. Next, we’ll...

ABT